Hormone Therapy Negatively Impacts African American Men

  A study found that African American men had a higher rate of death from non-prostate cancer problems than non-African American men after receiving short-term hormone therapy (ADT) prior to having brachytherapy (seeds). There are significant implications beyond this research.

Caution - Testosterone Flare During Transition from Degarelix to Leuprolide

Transitioning from Degarelix to Lupron can cause a dangerous PSA flare that needs to be avoided by adding an anti-androgen drug like Casodex prior to making the transition; not unlike when Lupron is started as an initial treatment.

A Fatal Flaw in the Clinical Trial Consenting Process

More than a majority of cancer patients do not understand that if they enter into a clinical trial they have no guarantee that they will receive the investigational treatment that they believe their doctor wants them to receive!  More transparent clinical trial consenting procedures need to be immediately instituted. 

Zytiga And Prednisone Provide Significant Benefits Beyond Survival With Newly Diagnosed Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer

Zytiga And Prednisone Provide Significant Benefits Beyond Survival With Newly Diagnosed Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer

Bisphosphonate Treatment for Men with Non-Metastatic Prostate Cancer Treated With ADT

The current standard of care for men with non-metastatic prostate cancer who are on hormone therapy (ADT) does not include the use of any of the bisphosphonate drugs.  Some men might benefit by using them at this stage.

Do You Want To Become A Peer Reviewer for the Department of Defense Prostate Cancer Program?

The Department of Defense Prostate Cancer Research Program is seeking Cancer Thrivers to participate as peer reviewers who will select which prostate cancer research programs will receive funding.

 

Do you want to participate as a reviewer?

Two Possible Clinical Trial End Points Predicting Survival and Death

The gold standard of clinical trial end points is survival.  Since prostate cancer tends to move relatively slowly it can take many years for a clinical trial to be completed.  We need better surrogate endpoints for survival so that trials can be completed more quickly allowing new drugs to flow to us.